Purpose: We evaluated the outcome of children (<15 years) versus that of adolescents and young adults (AYA; 15-≤ 21 years) treated for Hodgkin lymphoma (HL) in two Pediatric Oncology Group/Children's Oncology Group clinical trials, P9425 and P9426, that used dose-dense, response-based chemotherapy and reduced dose radiotherapy.
INTRODUCTION
Hodgkin Lymphoma (HL) is a curable malignancy affecting all age groups; in high-income countries, it is the most common malignant Abbreviations: ABVE, doxorubicin, bleomycin, vincristine, and etoposide; ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; AYA, adolescents and young adults; COG, Children's Oncology Group; EFS, event-free survival; HL, Hodgkin lymphoma; LP, lymphocyte predominant; MC, mixed cellularity; M/T, mass/toracic; NS, nodular sclerosis; OS, overall survival; POG, Pediatric Oncology Group; RER, rapid early response; SER, slow early response disease in adolescents. It is highly sensitive to chemotherapy and radiotherapy with cure rates greater than 80%. Modern treatment strategies for adults and children use somewhat different approaches to achieve these outcomes. Children are now treated with response-based, dose-dense therapies such as ABVE-PC (doxorubicin, regimens designed to optimize the balance between enhanced efficacy and reduced toxicity. Adults in the United States receive four to eight cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) based on stage and response while the dose-intensive escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and procarbazine) has been the primary approach for European adults with high-risk disease. [1] [2] [3] [4] The treatment for adolescent/young adult patients (AYA) ages 15-22 years has been determined by whether these young patients are referred to pediatric or medical oncologists. Eichenauer and Foltz showed progression-free survival of 76-80% for patients aged 15-18 versus 22-45 years using a variety of adult regimens. These data were used to justify the treatment of adolescents with adult regimens without consideration of potential benefits of pediatric-specific HL therapies in terms of efficacy, reduction of late effects, or quality of life.
Muller et al. reported, however, that adolescents of age 14-21 years treated with a pediatric regimen had better event-free survival (EFS) at 5 and 10 years than those treated with an adult regimen (ABVD). [5] [6] [7] In this report, we compared the outcomes of children versus AYA enrolled on two concurrent Pediatric Oncology Group (POG) trials for low-risk (P9426) and intermediate-/high-risk (P9425) HL. 1, 5, 6, 8 ABVE was used in P9426, while ABVE-PC was used in P9425.
The dose of each chemotherapeutic drug in ABVE and ABVE-PC was specifically selected to limit the cumulative dose below recognized thresholds for known long-term toxicities. 1, 8 Radiation dose was also reduced relative to contemporaneous adult regimens. In these trials, dose density was introduced to enhance early response rates.
Using response-based therapy, the total amount of chemotherapy was reduced for those patients achieving a rapid response. A secondary effect was the short duration of therapy (8-9 weeks of chemotherapy) for early responders, enabling AYA to return to peers, school, and work more rapidly.
If the results for children and adolescents are similar on the pediatric regimens, then it is reasonable to directly compare pediatric versus adult regimens based on overall efficacy, long-term toxicity, and quality of life in the specific context of AYA. The excellent outcomes for HL should encourage maximal cooperation between adult and pediatric investigators to ensure that we are delivering the optimal therapies to all AYA. We report herein our analysis of the outcome of pediatric versus AYA patients treated on P9425 and P9426 trials with the intent of assessing the value of treating AYA according to these pediatric regimens.
METHODS

Subjects
Subjects 21 years or younger with histologically proven HL were eligible for these studies. 
Therapy
The ABVE chemotherapy regimen in P9426, a modification of ABVD, replaced vinblastine and dacarbazine with vincristine and etoposide to maintain dose intensity while avoiding delays and reductions of therapy attributable to myelosuppression. For P9425, ABVE-PC chemotherapy regimen eliminated procarbazine and limited doses of doxorubicin and etoposide to decrease long-term adverse events.
Patients received two ABVE cycles (P9426) or three ABVE-PC cycles (P9425) before early response evaluation (Fig. 1) . Patients with rapid early response (RER) (≥50% two-dimensional reduction in tumor size, M/T ratio < 0.33, and negative gallium scan) proceeded to radiotherapy 25.5 Gy to the involved nodal chains defined prior to chemotherapy (involved field radiotherapy) for those subjects on P9426 or 21 Gy to involved and adjacent nodal chains (involved region radiotherapy) for those on P9425. Two additional chemotherapy cycles were given to patients with slow early response (SER) before the same radiotherapy.
Subjects received granulocyte colony-stimulating factor (5 g/kg/day) 
Statistical methods
We retrospectively analyzed the two POG studies, P9425 and P9426, and compared the survival rate of children to the survival rate of AYA.
For the purpose of our analysis, children were defined as subjects <15
years of age at diagnosis and AYA as those 15-≤21 years of age at diagnosis. Demographic variables were compared between the two age groups by chi-square test. EFS was defined as the minimum time from study enrollment to disease relapse/progression, second malignancy, or death due to any cause. Overall survival (OS) was defined as time from study entry to death from any cause or until last contact if subject did not die. Subjects without these events were censored at the time of last contact. EFS estimates were based on Kaplan-Meier product-limit method with confidence interval based on the "exponential" Greenwood formula. 9 The log rank test was used to investigate differences in EFS outcomes between groups.
Cox proportional hazards model was used to examine the association between multiple risk factors and EFS. 10 Patient follow-up was collected through June 2008. All P values were two-sided and P value < 0.05 was considered statistically significant. All analyses were performed in Stata version 12 (StataCorp., College Station, TX). (99/255) AYA on P9426 (P = 0.042). The evaluation of response to therapy according to study/risk group did not differ between AYA versus children for P9425. For P9426, the RER rate was 50.3% for children versus 37.8% for AYA (P = 0.052).
RESULTS
TA B L E 2 Comparison of cumulative doses of chemotherapy used in pediatric (P) versus adult (A) regimens
While this univariate analysis is of borderline significance, the data were not corrected for histology that may account for the difference in response. In the low-risk group, the histological subtype for chil- 
DISCUSSION
With OS for AYA with HL exceeding 90% in most trials, the future goals of clinical trials must not focus only on treatment efficacy but also on the benefits of each approach. The quality of life for AYA, while receiving chemotherapy and the reduction of long-term side effects in the survivorship years, is critically important. These important parameters will need to be addressed when treating AYA if the expectation is that disease outcomes are similar on all treatment regimens.
In this report, we present our combined analysis of the EFS and OS of AYA versus younger children in the clinical trials P9426 and P9425
for the treatment of HL. We did not find a statistically significant difference between the EFS and OS of AYA versus younger children either in the combined analysis or in analysis of each protocol separately.
The studies of Eichenouar and Foltz show that adolescents and adults have similar outcomes when treated on the same regimens.
However, a trial from Hungary found that the EFS of AYA was inferior when treated with an adult-based treatment regimens compared to a more dose-intensive pediatric regimen. Yung et al. reported that outcome for British adolescents of age 15-17 years treated according to older adult protocols was inferior to that reported in the literature for children. [5] [6] [7] 11 These findings may reflect benefit of dose-intensive therapies for AYA, but a direct comparison of pediatric and adult regimens could be impacted if there is truly a different response to therapy based on age. Such analyses also will need to take into account the impact of histology differences between children and AYA. Our study did not show evidence of an effect of histologic subtype in this pediatric/adolescent cohort.
AYA have equivalent results to adults when they are treated with a treatment regimen commonly used to treat adult subjects with HL. 5, 6 They also have similar EFS and OS to children when treated with a pediatric treatment regimen. The results obtained with either approach are excellent with OS greater than 80%. If this similarity of disease outcomes were confirmed, then the effect of different regimens in terms of quality of life and long-term survival becomes the major differentiator.
Excellent results come at a price. Both chemotherapy and radiotherapy have serious long-term adverse events including cardiac, endocrine, pulmonary complications, and risk for second malignancies.
Given the excellent results of therapy, future clinical trials must take into consideration decreasing long-term adverse effects of therapy while preserving the excellent OS. P9426 and P9425 were designed with these principles in mind. 1,9 P9426 for low-risk HL decreased the amount of medication based on response and substituted etoposide for dacarbazine from the ABVD regimen. P9425 eliminated procarbazine to protect fertility, but also intensified and compressed therapy per cycle with the intent of increasing the number of subjects achieving RER and thus decreasing the overall exposure to therapy (Table 2) .
Radiation doses and fields were also decreased when compared to the contemporaneous adult-based clinical trials. Both protocols were successful in decreasing total dose of therapy for over 50% of the subjects treated (RER) while preserving an excellent EFS and OS. The rapid delivery of therapy to AYA on these trials (with RER requiring only 8- 
